<DOC>
	<DOCNO>NCT02857816</DOCNO>
	<brief_summary>To evaluate NURO system treatment OAB drug naïve patient .</brief_summary>
	<brief_title>PRospective Study Evaluate EffectivenesS With NURO™ PErcutaneous Tibial Neuromodulation System Patients With OAB</brief_title>
	<detailed_description>The purpose prospective , multicenter , single arm study evaluate NURO system treatment OAB drug naïve patient . The study assess change baseline 12 PTNM therapy session UUI episode , void episode , patient report outcomes . The study expect last approximately 14 week per subject follow enrollment visit . Subjects exit study final study visit complete .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<criteria>1 . 18 year age old 2 . Diagnosis OAB associate symptom UUI qualify least 3 episode mild , moderate , severe urgency demonstrate 3day urinary void diary 3 . Experiencing UUI symptom least 3 month 4 . No prior treatment anticholinergics/antimuscarinics beta 3agonists medication treat OAB 5 . Willing able accurately complete void diary questionnaire , attend visit , comply study protocol 6 . Willing able provide sign date informed consent 1 . Have receive anticholinergics/antimuscarinics beta 3agonists medication treat OAB advance therapy treatment option OAB ( botulinum toxin injection , sacral neuromodulation , percutaneous tibial nerve stimulation/neuromodulation ) 2 . Primary stress incontinence mixed incontinence stress component override urge component 3 . Have implantable pacemaker implantable defibrillator 4 . Use transcutaneous electrical nerve stimulation ( TENS ) pelvic region , back legs 5 . Women pregnant plan become pregnant course study 6 . Characteristics indicate poor understanding study characteristic indicate subject may poor compliance study protocol 7 . Nerve damage could impact either tibial nerve pelvic floor function . 8 . Subjects prone excessive bleeding 9 . Inadequate skin integrity area PTNM needle placement 10 . History diabetes unless diabetes wellcontrolled diet and/or medication 11 . Have symptomatic urinary tract infection ( UTI ) 12 . Participation research study involve impact gynecologic , urinary renal function within 4week period prior plan participate study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>